Welcome to OriGene AI!

I'm your AI-powered guide to everything OriGene.
Ask me anything:

Product specs
Ordering help
Technical questions
How to find exactly what your experiment needs

Prefer a live agent? Connect with us by clicking the green chat icon, as seen in the image below or email our team at custsupport@origene.com.

Biomarker in Spotlight

Protein Tyrosine Phosphatase 1B

(PTP1B)

The first protein tyrosine phosphatase identified in humans — a dual-role clinical biomarker bridging metabolic dysfunction, cancer susceptibility , and neurodegeneration.

Explore Products

Read the Science

The Biomarker

What is PTP1B/PTPN1?

Protein Tyrosine Phosphatase 1B (PTP1B/PTPN1) was the first protein tyrosine phosphatase identified and purified from the human placenta. It is a widely expressed enzyme that acts as a critical regulator of signal transduction by removing phosphate groups from tyrosine residues on various proteins.

While historically known for its central role in maintaining glucose homeostasis and energy balance, PTP1B has emerged as a high‑value clinical biomarker due to its context‑dependent dual role in human diseases. It acts as a potential mediator between metabolic dysfunction and both cancer susceptibility and neurodegeneration.

Regulates signal transduction via tyrosine dephosphorylation

 Context‑dependent: oncogene OR tumor suppressor

 Links metabolic dysfunction to cancer and neurodegeneration

Expressed broadly across human tissues, especially brain and placenta

1st

First PTP Identified

In human placenta

3+

Disease Areas

Cancer, AD, Metabolic

Dual

Clinical Roles

Oncogene & Tumor Suppressor

10+

Signal Networds

Pathways regulated

Science & Mechanism

Biological Activity & Mechanisms

The biological activity of PTP1B is characterized by it's ability to modulate cell growth, differentiation, and metabolism across multiple disease contexts

In Solid Tumors

PTP1B exhibits a clinical duality, acting as either an oncogene or a tumor suppressor depending on the tissue and signaling environment. It often drives tumor growth by activating the Src signaling pathway through dephosphorylation of its inhibitory tyrosine residue.

Breast Cancer (HER2+)

Oncogenic

Required for HER2–driven transformation; activates ErbB2/ErbB3 signaling

Colorectal Cancer (CRC)

Promotes Growth

Activates Raf/mTORC1/PRAS40 pathway, stimulating proliferation

ER+ Breast Cancer

Tumor Suppressor

Acts as natural brake on estrogen signaling; inhibition may be detrimental

Glioblastoma (GBM)

Context‑Dependent

Modulates STAT3, Cyclin A, and CDK3 in cell cycle regulation

PTP1B regulates various cell signaling cascades — PTP1B regulates various cell signaling casacades in several cancers

PTP1B regulates multiple mechanisms in the pathogenesis of Alzheimer's diease

In Alzheimer's Disease

PTP1B is highly expressed in the brain, particularly in microglia, where it acts as a “molecular brake” on immune activation. Elevated PTP1B activity is linked to neuronal insulin and leptin resistance, which impairs cognitive function and promotes neuroinflammation.

● IRS‑2/AKT Pathway

PTP1B negatively regulates insulin signaling by dephosphorylating IRS‑1 and IRS‑2, inhibiting PI3K/AKT. In AD, this activates GSK3β — a kinase implicated in tau pathology and cerebral deposits.

● SYK–Phagocytosis Axis

In microglia, PTP1B directly dephosphorylates Spleen Tyrosine Kinase (SYK), suppressing AKT‑mTOR signaling. This reduces the clearance of toxic amyloid‑β aggregates.

● Neuroinflammation via NF‑κB

Elevated PTP1B triggers the NF‑κB cascade in microglia, upregulating COX‑2, TNF‑α, iNOS, and IL‑1β — driving chronic neuroinflammation.

● Synaptic Stability & Cognition

Suppresses BDNF/TrkB signaling and LepR/JAK2, impairing spine/synapse plasticity and driving cognitive decline.

Related Biomarkers

Studied Alongside PTP1B

These key biomarkers are frequently co-studied with PTPB1B, forming an interconnected signaling network across cancer, metabolic disease, and neurodegeneration.

SYK

Spleen Tyrosine Kinase

Identified as a direct substrate of PTP1B; its phosphorylation is a key indicator of microglial activation. SYK suppression by PTP1B reduces AKT–mTOR signaling and amyloid‑β clearance in Alzheimer’s disease.

Alzheimer’s Disease Microglial Activation

GSK3β

Glycogen Synthase Kinase 3β

Often considered alongside PTP1B in AD research. Its disinhibition — via low AKT activity caused by PTP1B — is a major driver of tau pathology, leading to hyperphosphorylation and neurofibrillary tangle formation.

Alzheimer’s Disease Tau Pathology

Src Kinase

Proto‑Oncogene Tyrosine‑Protein Kinase

A primary target activated by PTP1B dephosphorylation of its inhibitory Y527 residue. Studied in both cancer and neuroinflammation, downstream Erk1/2 activation promotes metastasis and cell survival.

Cancer Neuroinflammation

HER2/ErbB2

Human Epidermal Growth Factor Receptor 2

Frequently co‑studied in breast cancer models where PTP1B is required for HER2‑driven transformation. PTP1B inhibition in HER2+ tumors may be a viable therapeutic strategy, while caution is needed in ER‑ cases.

Breast Cancer HER2+ Tumors

Amyloid‑β (Aβ)

Amyloid Beta Peptide

The primary pathological hallmark of Alzheimer’s disease. Used to measure the efficacy of PTP1B‑targeted clearance therapies, as PTP1B inhibition restores microglial phagocytosis and reduces amyloid burden.

Alzheimer’s Disease Therapeutic Efficacy

IRS‑1 / IRS‑2

Insulin Receptor Substrates 1 & 2

Direct dephosphorylation targets of PTP1B. Their inhibition blocks the PI3K/AKT cascade, linking PTP1B activity to both insulin resistance (metabolic disease) and neurodegeneration in the brain.

Metabolic Disease Insulin Signaling

Research Tools

OriGene Solutions For PTP1B Research

Comprehensive tools and reagents to advance your PTP1B research from discovery to validation.

Featured Product

PTP1B (PTPN1) Mouse Monoclonal Antibody

Clone: OT12G3 . TA503188

Application: FC, IF, IHC, WB

IHC staining to assess PTP1B expression in prostate cancer tissue samples. Ref

Knockout validation of the antibody to ensure bind the target — Knockout validation of the antibody to ensure binding the right target

Immunofluorescent of COS7 cells expressing PTP1B

Research Trends

Where the Field is Heading

Three major scientific directions are shaping the future of PTP1B research and the therapeutics.

Drug Discovery

Targeting the "Undruggable"

Because the catalytic site of PTPs is highly conserved and polar, PTP1B was long considered “undruggable”. Current research is shifting towards allosteric inhibitors that bind to non-catalytic sites, such as the C-terminal domain, to achieve better selectivity over similar phosphatases like TCPTP.

Allosteric inhibitors represent the new frontier in PTP1B targeting

Neuroscience

Metabolic–Neuro Link

A growing trend in studying PTP1B as the molecular link between type 2 diabetes, obesity, and Alzheimer’s Disease, suggesting that repurposing metabolic drugs or using PTP1B inhibitors could treat the “brain hypometabolism” seen in dementia.

Bridging T2D, obesity, and dementia through a single molecular target

Oncology

Precision Oncology

Research now emphasizes stratifying patients by tumor subtype, as PTP1B inhibition may benefit those with HER2‑positive breast cancer but could be detrimental in ER‑positive cases where the enzyme acts as a natural tumor suppressor.

Patient stratification is critical — benefit or harm depends on subtype

Ready to Advance Your Reaseach?

Explore our comprehensive PTP1B research solutions and discover how OriGene can support your breakthrough discoveries.

Browse All Products

References

1 PTP1B Inhibition Promotes Microglial Phagocytosis in Alzheimer’s Disease Models by Enhancing SYK Signaling. Published in bioRxiv	PubMed: 40501708
2 Protein Tyrosine Phosphatase 1B in Solid Tumors: Unraveling Its Clinical Significance. Published in Revista de Investigación Clínica	PubMed: 41604870
3 Neuronal Protein Tyrosine Phosphatase 1B Hastens Amyloid β-Associated Alzheimer’s Disease in Mice. Published in The Journal of Neuroscience	PubMed: 31915254
4 Protein Tyrosine Phosphatase 1B (PTP1B): A Potential Target for Alzheimer’s Therapy? Published in Frontiers in Aging Neuroscience	PubMed: 28197094
5 Role of Protein Tyrosine Phosphatase 1B Inhibitor in Early Brain Injury of Subarachnoid Hemorrhage in Mice. Published in Brain Sciences	PubMed: 37239288

See All »